Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | METTL3 | Q86U44 | 11/20 | 0.38 |
| ▸ | METTL14 | Q9HCE5 | 11/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL27247438 | 0.93 | METTL3 (0.37) | HRH4METTL3METTL14SMN1; SMN2RAB9A | |
| SCHEMBL27247390 | 0.86 | METTL3 (0.39) | HRH4METTL3METTL14SMN1; SMN2RAB9A | |
| SCHEMBL27383634 | 0.85 | DAO (0.46) | METTL3METTL14SMN1; SMN2RAB9A | |
| SCHEMBL27247738 | 0.85 | METTL3 (0.38) | METTL3METTL14SMN1; SMN2RAB9AMTNR1A | |
| SCHEMBL30920223 | 0.85 | HRH4 (0.40) | HRH4METTL3METTL14SMN1; SMN2RAB9A | |
| SCHEMBL30920709 | 0.83 | MTNR1A (0.57) | HRH4SMN1; SMN2RAB9AMTNR1AMTNR1B | |
| SCHEMBL27383636 | 0.83 | EIF4A3 (0.47) | METTL3METTL14SMN1; SMN2RAB9AMTNR1A | |
| SCHEMBL27247099 | 0.82 | HRH4 (0.45) | HRH4METTL3METTL14SMN1; SMN2 | |
| SCHEMBL27382334 | 0.82 | RAB9A (0.40) | METTL3METTL14SMN1; SMN2RAB9AMTNR1A | |
| SCHEMBL30920247 | 0.78 | MTNR1A (0.41) | METTL3METTL14SMN1; SMN2RAB9AMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4601635-A2 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2024-06-20 | — | — | US | disclosed |
| WO-2024081748-A2 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | SLC6A19, SLC2A9, SLC6A3 | HRH4 2480/4885METTL3 2034/4885METTL14 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.